Ahmedabad: A clutch of Gujarat-based drugmakers has launched lower-cost versions of semaglutide following the molecule’s patent expiry in India, intensifying competition in the fast-growing diabetes and obesity therapy segment.Zydus Lifesciences, Torrent Pharmaceuticals, Sun Pharmaceutical Industries and Eris Lifesciences have each introduced branded formulations, with prices sharply undercutting the innovator drug.Zydus has launched Semaglutide under three brands, offering a reusable multi-dose pen designed to improve dosing flexibility and adherence. The company has indicated a monthly therapy cost of about Rs 2,200. Torrent Pharma has entered the segment with both oral and injectable versions, claiming to be the first domestic firm to offer the drug in both formats, with injectable therapy starting at Rs 3,999 per month.Sun Pharma has rolled out multiple strengths for diabetes and weight management, with weekly therapy costs ranging from roughly Rs 750 to Rs 2,000, depending on dosage. Eris Lifesciences, meanwhile, has introduced a vial-based format priced from around Rs 1,290 per month, with plans to launch a pen-device variant.Semaglutide, a GLP-1 receptor agonist, is widely used to improve glycaemic control and aid weight loss. Industry executives said wider availability and lower prices could expand access significantly, as India grapples with a rising burden of diabetes and obesity, though clinicians caution that the therapy requires medical supervision.
